Physician profile
John M Weeman
NPI 1801230222
$589.78
in general payments reported to CMS, 2019-2025
15 companies · $260 in 2025
The $260 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $65.81 · 2022: $73.68 · 2023: $85.72 · 2024: $104 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $450.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $97.16 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $97.15 | 2022-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $65.75 | 2023-2025 | Ubrelvy, Qulipta |
| Inspire Medical Systems, INC. | $49.52 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $40.81 | 2021-2025 | Gardasil 9, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.91 | 2022-2025 | Xifaxan |
| Lilly USA, LLC | $32.10 | 2024-2025 | Mounjaro, Zepbound |
| Dynavax Technologies Corporation | $27.90 | 2024 | Heplisav-B |
| Biohaven Pharmaceuticals, INC. | $26.19 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.75 | 2022 | |
| Eisai INC. | $23.25 | 2021 | |
| Noven Therapeutics, LLC | $21.37 | 2025 | Xelstrym |
| Glaxosmithkline, LLC. | $18.18 | 2025 | Arexvy, Shingrix |
| Astellas Pharma US INC | $15.75 | 2024 | Veozah |
| Astrazeneca Pharmaceuticals LP | $14.99 | 2025 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Weeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.